文献速递浆细胞疾病

多发性骨髓瘤中的CD38抗体:回到未来

CD38 antibodies in multiple myeloma: back to the future.
PubMed 文献 · Blood · 2017-11-08

CD38在多发性骨髓瘤(MM)细胞上高表达且表达均一,基于此开发了达雷妥尤单抗(全人源)、伊沙妥昔单抗(嵌合型)和MOR202(全人源)等CD38抗体。这些抗体通过Fc依赖性免疫效应、直接促凋亡及清除CD38阳性免疫抑制细胞等多重机制发挥作用;单药治疗在约30%经重度治疗的MM患者中诱导部分缓解或更好疗效,与免疫调节剂或蛋白酶体抑制剂联合可获得深度缓解并延长无进展生存期。

要点

  • CD38抗体单药在约30%经重度治疗的MM患者中诱导部分缓解或更好疗效。
  • CD38抗体与免疫调节剂或蛋白酶体抑制剂联合可在复发/难治MM中获深度缓解并延长无进展生存期。
  • 输注相关反应多发生于首次输注,CD38抗体可干扰部分实验室检测,影响疗效评估与输血相容性检测。

核心结论

  • CD38抗体机制独特、毒性谱良好且具单药活性,是联合方案中有吸引力的搭档,目前正在初诊及高危冒烟型MM中开展研究,并在其他血液恶性肿瘤及实体瘤中接受研究。

研究设计与样本

  • 综述,围绕CD38的生物学特征及CD38抗体(达雷妥尤单抗、伊沙妥昔单抗、MOR202)的作用机制、临床活性与联合应用进行总结。

主要发现

  • CD38在MM细胞上高表达且均一,在正常淋巴与髓系细胞及部分非造血组织上表达水平相对较低。
  • CD38为具胞外酶活性的跨膜糖蛋白,同时作为受体和黏附分子发挥作用。
  • CD38抗体具有多重作用机制,包括Fc依赖性免疫效应机制、直接促凋亡活性,以及通过清除CD38阳性免疫抑制细胞产生的免疫调节效应。
  • CD38抗体单药在约30%经重度治疗的MM患者中诱导部分缓解或更好疗效。
  • CD38抗体与免疫调节剂或蛋白酶体抑制剂联合时,复发/难治MM患者可获得深度缓解并延长无进展生存期。

关键数值与推荐

  • CD38抗体单药在经重度治疗的MM患者中部分缓解或更好疗效的比例约为30%。
  • 输注相关反应通常发生于首次输注,是最常见的不良事件。
  • 需注意CD38抗体对某些实验室检测的干扰,可能使疗效评估和输血相容性检测复杂化。

临床怎么用

  • CD38抗体一般耐受良好,基于其独特作用机制、良好毒性谱和单药活性,可作为联合方案中有吸引力的搭档。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD38 is highly and uniformly expressed on multiple myeloma (MM) cells, and at relatively low levels on normal lymphoid and myeloid cells, and in some tissues of nonhematopoietic origin. CD38 is a transmembrane glycoprotein with ectoenzymatic activity, and also functions as a receptor and adhesion molecule. Altogether, this has triggered the development of several CD38 antibodies including daratumumab (fully human), isatuximab (chimeric), and MOR202 (fully human). CD38 antibodies have pleiotropic mechanisms of action including Fc-dependent immune-effector mechanisms, direct apoptotic activity, and immunomodulatory effects by the elimination of CD38+ immune-suppressor cells. CD38-targeting antibodies are generally well tolerated and induce partial response or better in ∼30% of heavily pretreated MM patients as monotherapy. Based on their distinct mechanisms of action, favorable toxicity profile, and single-agent activity, CD38 antibodies are attractive partners in combination regimens. Indeed, deep responses and prolonged progression-free survival can be achieved in relapsed/refractory MM patients when CD38 antibodies are combined with immunomodulatory agents or proteasome inhibitors. Infusion-related reactions, which typically occur during the first infusion, are the most frequent adverse events. Attention should also be paid to the interference of CD38 antibodies with certain laboratory assays, which may complicate response evaluation and blood compatibility testing. Several studies are currently examining the role of CD38-based therapies in newly diagnosed and high-risk smoldering MM. Furthermore, CD38 antibodies are currently also under investigation in other hematologic malignancies, including acute lymphoblastic leukemia, natural killer/T-cell lymphoma, and acute myeloid leukemia, as well as in solid tumors.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. van de Donk NWCJ, Richardson PG, Malavasi F, et al. CD38 antibodies in multiple myeloma: back to the future. Blood. 2017. PMID: 29118010. doi:10.1182/blood-2017-06-740944

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。